Staud 2015.

Study characteristics
Methods	Design: parallel Duration: 6 weeks Assessment: baseline and post‐intervention Country: USA
Participants	Pain condition: fibromyalgia Population: adults with fibromyalgia Minimum pain intensity: ≥ 4 on 0‐10 VAS Inclusion criteria Fulfill the 1990 ACR criteria for fibromyalgia including widespread pain Exclusion criteria Significant comorbidities: MDD, anxiety disorders and other chronic illnesses Total participants randomised: 61 Age in years (mean, SD): NR Gender: 56/61 were female Pain duration in years (mean, SD): NR
Interventions	Placebo n = 30 Inert Identical appearance and matched dosing Milnacipran 100 mg n = 31 SNRI Fixed dose
Outcomes	Pain intensity Mood Withdrawal
Missing data methods	ITT with LOCF
Funding source	Pharmaceutical: This study was supported by an investigator‐initiated grant from Forest Laboratories. All study drugs were provided by Forest Laboratories.
Conflicts of interest	Funded by an investigator‐initiated grant from Forest Laboratories. All study drugs were provided by Forest Laboratories. The sponsors of this trial had no role in planning and implementing the study, and in the analysis of the data. They were not involved in the writing of this report. None of the authors have any financial or other relationships that might lead to a COI.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were randomised using Research Randomizer (http://www.randomizer.org/)
Allocation concealment (selection bias)	Unclear risk	Allocation procedure not specified
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blind, identical study drugs with matched dosing
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Self‐reported outcomes from blinded participants
Incomplete outcome data (attrition bias) All outcomes	High risk	Similar attrition in both arms, report that they will use LOCF for missing data but then state that as "missing data did not result in different conclusions, we report only the results of uncorrected analyses", so completer analysis. Attrition Total: 26/62 (41.9%) Placebo: 5/23 (21.7%) Milnacipran 100 mg: 6/23 (26.1%) 15 participants (8 milnacipran, 7 placebo) withdrew post‐randomisation prior to receiving study medication, so were not included in the arm‐specific totals above. No reasons were given for the withdrawals of these 15 participants.
Selective reporting (reporting bias)	High risk	Protocol only lists mechanical and heat hyperalgesia and clinical pain as outcomes. Doesn't specify how these will be collected or the other measures used in the study.
Other bias	High risk	Create a second baseline essentially: a lot of participants withdrew after randomisation and so the authors ignore that in final analysis and only include those who came back for a second study visit.